PAD Profile : Tocilizumab - Covid-19

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tocilizumab - Covid-19

PAD Profile : Tocilizumab - Covid-19

Keywords :

CMDU, covid medicines delivery unit, monoclonal antibody, MAB,

Brand Names Include :

RoActemRA, Tyenne

Traffic Light Status

Status 1 of 1.

Status :

Red

Formulations :

Not Specified

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type

Document

Review Date

Evidence Review

NICE TA878 CMDU APC briefing paper Jun-23.doc

Webpage

NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Committee Recommendations

Date

Committee Name

Narrative

05 July 2023

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Tocilizumab is agreed as RED only for administration in the hospital setting

Associated BNF Codes

05. Infections

05.03.06. Coronavirus